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Aims Patientswithwell-tolerated sustainedmonomorphic ventricular tachycardia (SMVT) and left ventricular ejection fraction
(LVEF) over 30%may benefit from a primary strategy of VT ablation without immediate need for a ‘back-up’ implantable
cardioverter-defibrillator (ICD).
Methods
and results
One hundred and sixty-six patients with structural heart disease (SHD), LVEF over 30%, and well-tolerated SMVT
(no syncope) underwent primary radiofrequency ablation without ICD implantation at eight European centres. There
were 139 men (84%) with mean age 62+ 15 years and mean LVEF of 50+ 10%. Fifty-five percent had ischaemic
heart disease, 19% non-ischaemic cardiomyopathy, and 12% arrhythmogenic right ventricular cardiomyopathy. Three
hundred seventy-eight similar patients were implanted with an ICD during the same period and serve as a control
group. All-cause mortality was 12% (20 patients) over a mean follow-up of 32+27 months. Eight patients (40%) died
from non-cardiovascular causes, 8 (40%) died from non-arrhythmic cardiovascular causes, and 4 (20%) died suddenly
(SD) (2.4% of the population). All-cause mortality in the control group was 12%. Twenty-seven patients (16%) had a
non-fatal recurrence at a median time of 5 months, while 20 patients (12%) required an ICD, of whom 4 died (20%).
Conclusion Patients with well-tolerated SMVT, SHD, and LVEF. 30% undergoing primary VT ablationwithout a back-up ICDhad a
very low rate of arrhythmic death and recurrences were generally non-fatal. These data would support a randomized
clinical trial comparing this approach with others incorporating implantation of an ICD as a primary strategy.
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Introduction
The occurrence of a sustainedmonomorphic ventricular tachycardia
(SMVT) in patients with underlying structural heart disease (SHD)
has traditionally been considered to carry a poor prognosis based
on historical data in patients treated with anti-arrhythmic drugs.1–3
Subsequently, randomized trials have proven the lifesaving benefit
of an implantable cardioverter-defibrillator (ICD) compared with
anti-arrhythmic drug therapy in patients with sustained ventricular
arrhythmias and SHD.4–8 However, patients included in these
trials presented with aborted cardiac arrest or poorly tolerated VT
causing syncope or severe haemodynamic compromise—all condi-
tions known to carry a poor prognosis9—while patients with well-
tolerated VT were excluded.
Based on these trials and a subsequent meta-analysis,8 ICD im-
plantation is currently recommended after the occurrence of a
SMVT in patients with SHD whether the arrhythmia is tolerated or
not, even in the presence of normal or near-normal ventricular sys-
tolic function.10 It is intuitively reasonable that the patients with well-
tolerated VT and preserved ventricular function will have a better
prognosis than the contrary and would be more likely to present
again with well-tolerated VT in case of recurrence. Such patients
were arguably underrepresented in the pivotal ICD trials and sub-
group analysis in all these trials supported the supremacy of ventricu-
lar function in prognosis with most ICD benefit occurring in the
groups with poorest ejection fraction (≤30%).
Radiofrequency (RF) ablation of VT has progressed substantively
since the initial pivotal ICD secondary prevention trials but is cur-
rently only indicated in patients at low risk for died suddenly
(SD).11 Radiofrequency ablation without ICD has been reported an-
ecdotally in patients with SHD and SMVT.12–15 A strategy of primary
RF ablation without concurrent ICD implantation in the subgroup of
patientswithwell-toleratedVTandpreserved left ventricular systolic
function has obvious potential advantages but has never been
assessed systematically.
Weperformed a retrospective Europeanmulticentre studyon the
follow-up of patients with SHD with a left ventricular ejection frac-
tion (LVEF) over 30% presenting with a well-tolerated first episode
of SMVTwhowere discharged after RF ablation as a primary strategy
without a concomitant ICD. We hypothesized that such patients
would have a relatively favourable prognosis and that recurrences,
if they occurred, would be non-fatal.
Methods
We reviewed consecutive SHD patients with LVEF over 30% admitted
for the occurrence of one or several well-tolerated first episode(s)
of SMVT and who were treated by RF ablation as a first choice therapy
at eight European tertiary reference centres (University Hospital Ran-
gueil, Toulouse, France; Ospedale San Raffaele, Milano, Italy; Univer-
sity Hospital, Berne, Switzerland; University Hospital Haut-Leveque,
Bordeaux-Pessac, France; University Hospital Leiden, Netherlands;
CentreHospitalierUniversitaireVaudois, Lausanne, Switzerland;Univer-
sity Hospital Lille, France; University Hospital Nancy, France) between
2005 and 2010 and who were discharged without ICD implantation.
Structural heart disease was defined by the existence of a chronic patho-
logical process generating an electrophysiological substrate for ventri-
cular arrhythmias—i.e. scar-related SMVT. Well-tolerated SMVT was
defined by the lack of syncope or cardiac collapse at the time of SMVT
presentation. Updated follow-upwas performedmid-2011 after review-
ing hospitalization and consultations reports, ICD interrogations (for the
patients eventually implanted during the follow-up), calling the cardiolo-
gists and/or physicians about the vital status of the patients and checking
death certificates when needed.
We collected clinical parameters, electrophysiological characteristics
of the clinical arrhythmias, details of the ablation procedure cause of
death, and recurrences of SMVT.
Died suddenly was defined as instantaneous or unexpected death oc-
curring less than 1 h after onset of symptoms, or death while sleeping or
unwitnessed.16 ‘Died suddenly’ was attributed to ventricular arrhythmia
unless otherwise documented. Deaths in patients with end-stage heart
failure were classified as ‘non-sudden’ regardless of terminal ventricular
tachyarrhythmias. Recurring SMVT was defined as ‘recurrence’ regard-
less of similarity to presenting VT.
The main endpoints of the study were mortality and VT recurrence
rates in non-implanted patients; thus follow-upwas ‘officially’ terminated
at the time of ICD implantation if eventually required. Nonetheless, sur-
vival andoccurrenceof appropriate therapies for ventricular arrhythmias
as retrieved from ICD memories continued to be documented in the
latter group.
Patients with SHD with LVEF. 30% and similar SMVT (no syncope)
implanted with an ICD at our eight centres during the same period of
time served as a control group.
Statistics
Continuous variables were reported as means+ SD ormedians (range)
as appropriate. Comparisons of continuous variables between groups
were performed with Student’s t-test or the non-parametric Mann
Whitney test as suitable. Categorical variables were compared with the
Chi-square test.
Univariate andmultivariate Cox regressionmodels were used to inves-
tigate the association between variables and mortality or SMVT recur-
rences during the follow-up and to determine hazard ratios (HR) and
95% confidence intervals (95% CI). All variables associated with a
P-value, 0.1 in univariate analysis were introduced in a multivariate
Coxmodel. The proportional-hazard assumptionwas tested for each cov-
ariate by the ‘log–log’ method, plotting (2ln[2ln(survival)]) for each cat-
egory of a nominal covariate vs. ln(analysis time). A backward procedure
was applied to assess variables that were significantly and independently
associated with mortality or SMVT recurrence. All tests were two-tailed,
and a P-value ,0.05 was considered to indicate statistical significance.
Results
Clinical and electrophysiological
characteristics
From 2005 to 2010, 166 consecutive SHD patients with well-
tolerated SMVT and LVEF over 30% were treated by RF ablation
without implantation of an ICD at our eight centres. Clinical para-
meters of the study population and characteristics of the SMVT are
depicted in Tables 1 and 2.
Themajority hadonlypalpitations (93patients, 56%)and twowere
completely asymptomatic. Others had pre-syncope (35 patients,
21%), congestiveheart failure (24 patients, 14%, onewith cardiogenic
shock), and chest pain (15 patients, 9%). Outside the fact that SMVT
was well-tolerated together with a LVEF . 30% and the success of
the ablation procedure, the main other reasons for not implanting
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an ICD were an ‘advanced’ age (.75 years old in 18 patients, 11%),
significant comorbidities and/or limited life esperancy in 7 (4%),
patients decision in 8 (5%), an electrical storm or multi-recurrent
VT (n ¼ 21, 13%) or slowVT (n ¼ 2) successfully stopped by the ab-
lation, orayoung age in2. The remaining casesdonothaveany reason
but the ones mentioned above.
Radiofrequency ablation
One hundred eighty-seven RF ablation procedures were performed
(15 and 3 patients needed two and three procedures, respectively).
Characteristics and results of the ablation procedure are depicted
in Table 3.
Procedure-related complications were reported in 11 patients
(6.5%), including tamponade (3) and atrio-ventricular block (2)
and pericardial effusion (1), groin haematoma (4) and femoral
peudo-aneurysm (1). One of the two patients with atrio-ventricular
block required a pacemaker. Therewas nomortality directly or indir-
ectly related to the ablation procedure.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table2 Characteristics of the sustained monomorphic
ventricular tachycardia
Number of episodesa Median 2 (1–14)
multiple (precise data NA) 15 patients 9%
Incessant 17 patients 10%
Electrical stormb 20 patients 12%
VT rate Median 160 bpm
(100–270 bpm)
VT rate ≥ 200 bpm 25 patients 15%
VT rate ≤ 200 and .150 bpm 88 patients 53%
VT rate ≤ 150 and .120 bpm 45 patients 27%
Slow VT (≤120 bpm) 9 patients 5%
Incessant slow VT 2 patients 1%
VT morphology
One VT morphology 154 patients 93%
Two VT morphologies 11 patients 6.5%
.2 morphologies 1 patient (5 different VT
morphologies)
aConsecutive episodes occurring in a short lapse of time before referral.
bDefined by the occurrence of at least three SMVT episodes over 24 h (comprising
patients with incessant VT).
Table 3 Characteristics and results of the ablation
procedure for sustained monomorphic ventricular
tachycardia (SMVT)
Inducible SMVT before ablation 149/166 90%
Numberof different induced SMVT median 1 (1–6)
Entrainment mapping 76/149 51%
SMVT termination during ablation 83/132a 63%
Pace mapping 131/164 80%
Percutaneous epicardial ablation 22/163 13%
Linear ablation 66/166 40%
Ablation of post-systolic potentials 73/165 44%
Tridimensional navigation system 116/166 70%
Irrigated catheter 153/165 93%
Procedural duration (min) 158+66 (40–430)
Fluoroscopy time (min) 27+14 (1–70)
Radiofrequency application (min) 13+10 (1–60)
All clinical/inducible SMVT
targetted
144/162 89%
No SMVT inducible after RF 137/158 87%
SMVT still inducible after RF 21/158 13%
Clinical SMVT 6/21
Non-clinical VT 15/21 (fast SMVT
or VF in11)
No electrophysiological testing
after RF
6/166 3.5%
aWhen radiofrequency was delivered during SMVT.
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Table 1 Clinical parameters of the study population
(n 5 166)
Male gender 139 patients 84%
Age (years) 62+15 (17–89)
LVEF (%) 50+10 (31–73)
LVEF .30 and ,45% 50 patients 30%
LVEF ≥45 and ,55% 63 patients 38%
LVEF ≥55% 53 patients 32%
NYHA class
Class I 77 patients 53%
Class II 60 patients 41%
Class III (data not available in 20 patients) 9 patients 6%
Underlying structural heart diseases
Ischaemic heart diseasea 91 patients 55%
Non-ischaemic cardiomyopathy 31 patients 19%
Arrhythmic right ventricular
cardiomyopathy
20 patients 12%
Valvular heart disease 6 patients 3.5%
Congenital heart diseaseb 5 patients 3%
Post-myocarditis 5 patients 3%
Hypertrophic cardiomyopathy 2 patients } 5%Undetermined cardiomyopathy 2 patientsAmyloidosis 1 patientIdiopathic left ventricular diverticle 1 patientPost traumatic/surgery 1 patient
Left ventricular myxoma 1 patient
Antiarrhythmic therapy at the time of VT occurrence
Beta-blockers 50 patients 30%
Amiodarone 21 patients 13%
Beta-blockers + amiodarone 31 patients 19%
Sotalol 11 patients 7%
Class 1 drug + beta-blockers 2 patients 1%
Class 1 drug + sotalol 1 patient 0.5%
No drug (data not available in 2 patients) 48 patients 29%
aRemote myocardial infarction (median 78 months before, one week to 33 years).
bRepaired tetalogy of Fallot in three, pulmonary atresia in one, and complex
congenital cardiomyopathy in one.
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At discharge, amiodarone was prescribed to 8 patients, beta-
blockers to 72, amiodarone + beta-blockers to 28, sotalol to 16,
and class 1 drugswith orwithout beta-blockers to 5.No antiarrhyth-
mic drugs were prescribed for 37 patients.
Follow-up
The mean follow-up was 32+27 months (1 week to 134 months),
leading to a cumulative follow-up of 437 patient-years. Follow-up
duration in living patients was never less than 6 months except for
5 patients early implanted after discharge (see below). No patient
was lost to follow-up.
Mortality
Twenty patients died (all-cause mortality 12%—i.e. 4.5% annual
mortality rate) at a median time of 25 months after catheter ablation
(1week to83months).Actuarial survival curve forall-causemortality
is shown in Figure 1.
Of these 20 patients, 8 (40%) died fromnon-cardiovascular causes
(1week to36months,median18), 8 (40%)died fromnon-arrhythmic
cardiovascular causes (6–83 months, median 27), and 4 patients
(20%) died suddenly (1–75months,median 37); nonewith recurrent
SMVT before the fatal event. No patient with end-stage heart failure
had documented terminal VT. Details related to mortality rates and
causes of death aredepicted in Tables 4 and5. Actuarial survival curve
for SD is shown in Figure 2.
Parameters significantly related to all-cause mortality in univariate
and multivariate are listed in Table 6.
A total of 378 patients were implanted for well-tolerated MSVT
and LVEF. 30% at our eight centres during the same period of
time (86% men, 63+13 years old, 76% ischaemic heart disease,
LVEF 43+10%). All-cause mortality in the comparison group for
the same follow-up duration was 12% (46 patients).
Ventricular tachycardia recurrences
Sustained monomorphic ventricular tachycardia recurred in 27
patients after the initial RF ablation (16%, i.e. 6% mean annual recur-
rence rate) at a median time of 5 months after the procedure (3 days
to 41 months). Actuarial survival curve without SMVT recurrence is
shown in Figure 3.
Figure 1 Actuarial survival curve for all-cause mortality.
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Table 4 Mortality rates and causes of deaths in the
patient’s population (n5 166)
All-cause mortality 20/166 (12%)
Non-cardiac mortality 8/166 (4.8%)
Neoplasy 2
Renal failure 1
Pulmonary cause 2
Neurologic deterioration 1
Cachexy 1
Exact cause NA 1
Cardiac non-arrhythmic mortality 8/166 (4.8%)
Refractory heart failure 7
Electro-mechanical dissociation 1
Sudden death 4/166 (2.4%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table5 Details about the four patients presenting with
sudden death during the follow-up
Delay after
ablation
(months)
1 33 42 75
Underlying
heart
disease
Valvular Ischaemic Ischaemic Ischaemic
Gender Male Male Male Male
Age 77 76 60 81
LVEF (%) 65 50 50 43
VT rate (bpm) 140 170 160 135
Symptoms Palpitations Near
syncope
Chest
pain
Near
syncope
Inducible after
ablation
NA No No Fast VT
Figure 2 Actuarial survival curves for sudden death.
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Recurrent SMVTwas similar inmorphology and rate to the ablated
one in 17 patients (63%), different in 8 (30%), and not available in
2. Recurrencewas not statistically associatedwith all-causemortality.
Recurrence was correlated only with female gender with borderline
significance (HR 2.20, 95% CI 0.92–5.23, P ¼ 0.07).
Of these 27 patients, 5 had ICD implanted at this time, 8 were dis-
charged without further RF ablation or ICD (1 non-sudden cardiac
death, no SMVT recurrence), while 14 patients underwent a
second RF ablation. Six of these 14 patients were finally implanted
because of failure of the second procedure, recurring SMVT, or
further recurrences despite repeated ablation procedures. From
this group of 14 patients, none of the ablated patients without ICD
died during the follow-up. The follow-up of patients with recurring
MSVT is summarized in Figure 4.
There was no significant differences in mortality or recurring
SMVT rates according to the main underlying heart diseases: 14%
mortality (3 SD) and 15% SMVT recurrences for ischaemic heart
disease, 13%mortality (no SD) and 26% SMVT recurrences for non-
ischaemic cardiomyopathy, and no mortality and 25% SMVT recur-
rence for arrhythmogenic right ventricular cardiomyopathy (P ¼ ns).
Implantable cardioverter-defibrillator
implantation
During the follow-up, 20 patients (12%)were implantedwith an ICD:
11 after SMVT recurrences (see above) and 9 without any
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Table 6 Parameters significantly related to all-cause mortality in univariate and multivariate analysis
Parameter Non adjusted HR 95% CI P Adjusted HR 95% CI P
Age* 1.14 1.08–1.21 ,0.0001 1.12 1.05–1.20 0.0007
All SMVT not targetted 5.82 2.26–14.94 0.0003 3.89 1.20–12.64 0.02
NYHA class
III vs. I 7.19 1.92–27.02 0.003 – – –
III vs. II 5.59 1.57–20.00 0.008 – – –
LVEF ≤ 45% 3.70 1.51–9.09 0.004 0.6 0.21–1.74 0.35
Female gender 3.10 1.08–8.92 0.03 3.09 0.97–9.81 0.05
SMVT rate** 1.02 1.00–1.03 0.04 1.002 0.98–1.02 0.8
Slow SMVT 3.36 0.97–11.63 0.05 – – –
Congestive heart failure 2.47 0.93–6.55 0.07 1.05 0.27–4.04 0.9
Electrical storm 2.37 0.86–6.54 0.09 2.62 0.83–8.26 0.1
Therewas a 14% increase in all-causemortality for each yearmore (*) and a 2% increase in all-causemortality for each bpm less (**). Slow SMVT not included in themodel because of
redundancy with SMVT rate, NYHA class also not included because of incomplete data.
Figure 3 Actuarial survival curve for recurrence of sustained
monomorphic ventricular tachycardia after the initial ablation pro-
cedure.
Figure 4 Summary of the follow-up of patients with recurring
sustained monomorphic ventricular tachycardia (upper) and of
implanted patients (lower).
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recurrence. The latter were implanted because of inducible SMVT
during electrophysiological study performed during the follow-up
at some centres (six cases), need for resynchronization therapy
(one case), and implantation in patients followed later on at other
centres (two cases). Median time to implantation was 6 months
(1–114).
Recurring arrhythmias with appropriate ICD therapies occurred
in 50% (4/8) of the implanted patients without SMVT recurrence
after ablation and in 78% (7/9) of the patients implanted because
of SMVT recurrences following ablation (NA in three cases) (P ¼
0.23). The recurring arrhythmias were monomorphic ventricular
tachycardia in all but one case (ventricular fibrillation).
Fourof the20 implantedpatients diedduring the follow-up (1 from
tamponade complicating the ICD implantation, 1 from intractable
heart failure, and 2 from non-cardiac causes 25, 12, and 31 months
after ablation, respectively), all of them having been implanted after
SMVT recurrence. The follow-up of implanted patients is summar-
ized on Figure 4.
All-cause mortality in non-implanted patients (20/146, 14%) was
lower than in implanted patients (4/20, 20%) although non-
significantly (P ¼ 0.45).
Discussion
All-cause mortality, sudden death, and
recurrences after radiofrequency ablation
of sustained monomorphic ventricular
tachycardia
This study suggests that a strategy of catheter ablation with a deferral
of ICD implantation is reasonable for the patient presenting with
well-tolerated SMVT related to structural disease with LVEF .
30%. All-cause mortality was 12% over a mean follow-up of 32
months, with a median time to death of 23 months. Importantly,
only four patients died suddenly (2.4% of the study population).
Even if no comparison could be made due to the lack of random-
ization, it should be noted that the all-cause mortality rate in the
control group of implanted patients presenting with SMVT and
sharing similar clinical characteristics was very similar (12%). These
data further compare most favourably with mortality rate in a
similar group of patients with SHD and stable SMVT included in the
AVID registry (of whom one-third were implanted with an ICD).17
In a small recent retrospective series of coronary artery disease
patients with SMVT, the 4-year mortality rate of 26 ablated patients
without ICD was even lower than that of 19 similar patients who
were later implanted because of inducibility at control testing.15
The sudden death rate was reassuringly low in our population, com-
paring favourably with the sudden death rates in treated groups of
large primary prevention trials.18–20 Hence, 162 of 166 patients
(97.6%) would have not benefited from initial implantation of an
ICD in this population. Of note, the patients included in this study
underwent successful ablation and presented with well-tolerated
VT (no syncope) and with moderately altered left ventricular func-
tion, representing a selected subgroup felt to be at relatively low
risk and carrying a probable better outcome. Moreover, some had
additional reasons for not being implanted (see results). These
results can clearly not be extrapolated to the broader population
of SHD patients with SMVT.
The SMVT recurrence rate was 16% with a median time to recur-
rence of 5 months after the RF ablation procedure. None of the 27
patients with documented recurring SMVT suffered a cardiac arrest
at the time of relapse and none of the 4 patients with SD did
present with recurring SMVT before. It is impossible to determine
if a relapse of the clinical-ablated SMVT was linked to the fatal
event in the four patientswhoexperienced SD, but the chronological
occurrence of SD and SMVTwas clearly different (all but one SMVT
occurredduring thefirst30months, all but oneSDoccurred after the
30th month) (see survival curves). Therefore, we hypothetized that
SD were not caused by recurrences of ablated MSVT, but were
more probably linked to the evolution of the underlying heart
disease (acute coronary event, decreased EF, and so on). In view of
our results however, the implantation of an ICD appears warranted
after a first relapse of SMVT since repeated RF ablationwas less likely
to be successful.
The prognosis following SMVT in patients with underlying SHD
has repetitively been considered to be poor. In historical series of
patients under various antiarrhythmic drugs, high recurrence and
mortality rates were observed.1–3 However, the risk of death of
patients with SHD and SMVT may not be as high as previously
thought and should not be assumed to be similar to the risk following
resuscitated SD.12 Indeed, low SD rates (,3% annual) in patients
with coronary artery disease and haemodynamically stable SMVT
or preserved LVEF were observed with anti-arrhythmic drugs even
before the era of the ICD.9,21,22 Although haemodynamically toler-
ated SMVT was associated with a high mortality rate in the AVID
registry, mortality of these patients was high in spite of the fact that
approximately one-third of the patients were given ICDs and
details about SD rate in non-implanted patients are missing.17 Our
results extend former observations reporting that mortality in
patients with haemodynamically tolerated SMVT was mainly due to
non-arrhythmic causes12 and possibly not preventable by ICD
implantation.
We can observe that the 4.5% all-cause-mortality annual rate in
our non-implanted patients treated by RF ablation is lower than
that of implanted patients in secondary prevention trials5–7 as well
as to that of patients implanted for SMVT in a more recent study23
and to that of ablated and mostly implanted patients with SMVT in
a recent large registry.24 However, LVEF was lower and haemodyna-
mical tolerance of the SMVT was poor or not detailed in all these
studies. The SD rate in this study is even substantively lower than
the arrhythmic death rate observed in implanted patients in
primary prevention trials.18–20
Implantable cardioverter-defibrillator
implantation
Only 20 patients (12%) eventually required an ICD in this study. The
implantationof an ICDafter theoccurrenceof a sustained ventricular
arrhythmia inpatientswith SHD is supportedbyprospective trials4–8
and current guidelines.10
Nonetheless, these trials predominantly included patients with
resuscitated cardiac arrest or with VT causing symptoms of serious
haemodynamic compromise. The improved outcome after ICD
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implantation in subgroup analysis was confined largely to patients
with LVEF, 35%8 or in patients ,75 years old.25 The latter
support a differential approach tomanagementof patients presenting
with VT based on risk stratification.12 A strategy of primary ablation
with deferral of ICD implantation in our patient population is consist-
ent with this view and is supported by the low sudden death rate in
our cohort.
Withholding ICD therapy in the lower risk subgroups towhich this
strategy is applicable has merit well beyond potential cost savings.
Although ICDs are life-saving in the appropriate patients, it is well
appreciated that ICDs still involve significant morbidity and even
mortality in their own right.15,23,26–32
The role of catheter ablation in the patient
with sustained monomorphic ventricular
tachycardia
Catheter ablation has a well-established role in managing recurrent
VT to reduce shocks in patients with ICDs. Advances in catheter
ablation promise to expand its role as an early treatment or even
alternative to ICD placement in selected individuals.12–14,33,34
Conclusion
These data support the view that a lower risk subgroup of patients
presenting with SMVT in the context of SHD can be identified and
that a uniform management imperative of an ICD may not be
optimal. Patients with LVEF. 30% and well-tolerated VT in our
cohort undergoing a primary VT ablation strategy had a low
sudden death rate compared with that observed in the treatment
arms of primary prevention trials and that VT recurrences were pre-
dominately non-fatal. A prospective randomized clinical trial to
evaluate the potential benefit and cost-effectiveness of an initial strat-
egy of catheter ablation with deferral of ICD implantation after a first
episode of well-tolerated SMVT in patients with moderate SHD
would be ethical and appropriate.
Limitations
This is a retrospective cohort analysis with all the inherent limitations
of such a study. The study was multicentre with no single ablation
strategy enforced. The follow-up is relatively short. Nonetheless, it
is the largest series to address the question and the sudden death
rate potentially arrhythmic was impressively low. This suggests that
a subgroup of patients with well-tolerated VT and non-severely
depressed ventricular function can be identified and managed
safely by a strategy of catheter ablation with deferral of ICD
therapy to a later stage in the management process if it becomes
obvious that it is necessary.
Conflict of interest: none declared.
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